Related Experiment Video

Updated: Jun 27, 2026

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Guggulsterone inhibits angiogenesis by blocking STAT3 and VEGF expression in colon cancer cells

Eun Soo Kim1, Sung Yi Hong, Hye Kyung Lee

  • 1Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul 120-752, Korea.

Oncology Reports
|November 21, 2008
PubMed

Insights

Guggulsterone, a plant sterol, shows promise in treating colon cancer by inducing apoptosis and inhibiting angiogenesis. It effectively blocks key proteins like STAT3 and VEGF, crucial for tumor growth and spread.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Guggulsterone, a plant sterol, exhibits anti-tumor properties.
  • Colon cancer is a significant global health concern requiring novel therapeutic strategies.
  • Angiogenesis plays a critical role in tumor progression and metastasis.

Purpose of the Study:

  • To investigate the anti-tumor effects of guggulsterone on colon cancer cells.
  • To elucidate the molecular mechanisms of guggulsterone's action, focusing on angiogenesis.
  • To evaluate guggulsterone's therapeutic potential for colorectal cancer.

Main Methods:

  • Cell viability assays to assess apoptosis.
  • Western blot to quantify protein expression (STAT3, VEGF, HIF-1alpha, ARNT).
  • Chromatin immunoprecipitation to analyze transcription factor binding to the VEGF promoter.
  • Endothelial cell assays (tube formation, migration) and zymography for MMP activity.

Main Results:

  • Guggulsterone significantly reduced colon cancer cell viability and induced apoptosis.
  • It suppressed VEGF, ARNT, and STAT3 expression, particularly under hypoxic conditions.
  • Guggulsterone inhibited STAT3 and ARNT recruitment to the VEGF promoter.
  • Reduced endothelial cell migration, tube formation, and MMP-2/-9 activity were observed.

Conclusions:

  • Guggulsterone demonstrates therapeutic potential for colorectal cancer by inducing apoptosis.
  • It inhibits angiogenesis and metastasis through the blockade of STAT3 and VEGF signaling pathways.
  • Guggulsterone represents a promising candidate for chemotherapeutic development against colon cancer.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

HUVEC Tube-formation Assay to Evaluate the Impact of Natural Products on Angiogenesis06:12

HUVEC Tube-formation Assay to Evaluate the Impact of Natural Products on Angiogenesis

Published on: June 24, 2019

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...